세계 백신 시장 규모는 2023년 1,413억 달러에서 2024년부터 2031년까지 예측 기간 동안 3.05%의 CAGR로 2031년에는 1,796억 9,000만 달러 규모로 성장할 것으로 예상됩니다.
세계 백신 시장은 암 백신 연구에 대한 자금 투입 증가, 백신 접종 캠페인에 대한 정부 지원 이니셔티브, DTaP 백신에 대한 수요 증가, 결합 백신 사용 증가, 환자 지원 및 교육 이니셔티브 증가 등에 의해 형성되고 있습니다.
암 백신 연구에 대한 자금 투입 증가
세계 백신 시장의 확대는 암 백신 연구에 대한 자금 조달 증가에 크게 의존하고 있습니다. 기술 혁신을 촉진하고 암 백신 개발을 가속화하기 위한 정부 프로그램에는 보조금, 보조금, 세제 혜택 등이 포함됩니다. 이러한 자금 지원을 통해 과학자들은 중요한 임상시험을 수행하고, 면밀한 연구를 수행하며, 암과 싸우기 위해 특별히 고안된 새로운 백신 접종 기술을 연구할 수 있습니다. 이러한 자금 지원은 백신이 엄격한 안전 요건을 충족하고 시장의 신뢰를 얻을 수 있도록 보장하여 백신의 성공적인 상용화를 위한 문을 열어줄 것입니다.
백신 접종 캠페인에 대한 정부의 노력
세계 각국 정부는 백신 접종 정책과 프로그램을 통해 세계 백신 시장에 큰 기여를 하고 있습니다. 백신 접종 캠페인은 많은 사람들과 어린이들에게 백신을 신속하게 투여하는 수단입니다. 국가적 필요와 목표에 따라 국가 또는 준국가적 차원에서 단일 항원 또는 복합 항원에 대해 시행될 수 있습니다. 이러한 활동을 후원함으로써 백신에 대한 공평하고 평등한 접근을 보장하는 동시에 백신의 중요성과 신뢰성에 대한 대중의 지식을 높일 수 있습니다. 이 전략은 백신 접종에 대한 수용성을 높이고, 예방접종률을 높이며, 지역사회의 건강 상태를 개선하는 데 도움이 될 수 있습니다. 또한 정부는 종종 백신에 대한 속설과 일반적인 불안을 없애고 지역 사회의 신뢰를 구축하기 위해 교육 이니셔티브에 자금을 지원하기도 합니다.
DTaP 백신 수요 확대
세계 백신 시장은 DTaP(디프테리아, 파상풍, 백일해) 백신 접종에 대한 수요 증가로 인해 성장하고 있습니다. 이러한 수요 증가의 주요 이유는 백일해, 파상풍, 디프테리아를 포함한 질병 발생률 증가에 대한 대응이 필요하기 때문입니다. 높은 출산율과 백일해 백신 접종에 대한 수용성 확대가 DTaP 백신 시장의 주요 촉진요인으로 작용하고 있으며, DTaP 성분을 포함한 혼합 백신의 출시도 시장 성장에 기여하고 있습니다. 이러한 수요를 충족시키기 위해 정부와 제약사들은 R&D에 대한 투자를 늘리고 있으며, 이는 세계 백신 시장의 혁신과 성장에 박차를 가하고 있습니다.
세계 백신 시장을 조사했으며, 시장 정의와 개요, 시장 규모 추이 및 예측, 각종 부문별·지역별 상세 분석, 산업 구조, 시장 성장에 영향을 미치는 요인 분석, 사례 연구, 경쟁 상황, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.
The global vaccine market is projected to witness a CAGR of 3.05% during the forecast period 2024-2031F, growing from USD 141.3 billion in 2023 to USD 179.69 billion in 2031F. The global vaccine market is shaped by increasing funding for cancer vaccine research, supportive government initiatives for vaccination campaigns, increased demand for DTaP vaccines, growing use of conjugate vaccines, and an increase in initiatives to support and educate patients.
The development of vaccinations against different types of malignancies has been made possible by increased funding in research, which has had a significant impact on the global vaccine market. The possibility of using immunological therapies to prevent or treat cancers increases with advances in scientific understanding. A surge in the demand for vaccinations against diphtheria, tetanus, and pertussis in the global vaccine market suggests that parents are becoming more conscious of diseases that can be prevented and are eager to shield their kids from potentially fatal conditions like whooping cough.
The initiatives taken by the governments are one of the major reasons for the substantial growth of the global vaccine market. Governments worldwide are actively promoting vaccination programs as part of their public health strategies. By supporting these efforts with resources and policy changes, governments aim to improve accessibility and coverage rates for essential vaccinations. The capacity of conjugate vaccines to offer enduring defense against bacterial infections, such as Streptococcus pneumoniae, Neisseria meningitidis serogroup C, and Haemophilus influenzae type b (Hib), has led to their increased popularity in the global vaccine market. Moreover, their rapid adoption around the world is largely due to their efficacy and safety profile.
Building trust between healthcare practitioners and patients is greatly aided by initiatives to educate and empower patients about the advantages and hazards of vaccinations. These kinds of programs also assist in clearing up misconceptions about vaccinations, which improves general adherence to advised schedules, leading to growth in the global vaccine market.
Pfizer India and Apollo Hospital jointly opened a Centre of Excellence (CoE) for adult immunization in Hyderabad in May 2023. Apollo Hospital aimed to safeguard patients from vaccine-preventable diseases (VPDs) and increase adult vaccination adoption through the establishment of an end-to-end ecosystem within the hospital.
Increased Funding for Cancer Vaccine Research
The expansion of the global vaccine market is largely dependent on increased financing for cancer vaccine research. Government programs that promote innovation and hasten the development of cancer vaccines include grants, subsidies, and tax breaks. This funding allows scientists to undertake critical clinical trials, carry out in-depth investigations, and investigate novel vaccination technologies that are specifically designed to fight cancer. This financing opens the door for the successful commercialization of vaccines by guaranteeing that they meet strict safety requirements and acquire the confidence of the market. This eventually improves public health outcomes and advances medical research in the battle against cancer.
For example, in June 2023, Pancreatic Cancer North America (PCNA) and Stand Up to Cancer (SU2C) announced PCNA's contribution of USD 1.5 million to SU2C to support pancreatic cancer vaccine development. The trial's vaccination was specifically designed to identify the cancer cells found in each participant's pancreatic cancer tumor and boost the immune system's ability to combat the malignancy.
Government Initiatives for Vaccination Campaigns
Governments across the globe are driving substantial contributions to the global vaccine market using vaccination policies and programs. Vaccination campaigns are a means of promptly administering vaccines to a large group of people or children. Depending on the needs and goals of the nation, they can be carried out at the national or sub-national level, for a single antigen, or in combination. Through their sponsorship of these activities, they ensure fair and equal access to vaccines, while increasing public knowledge of their importance and dependability. This strategy encourages greater vaccination acceptance, which raises immunization rates and improves community health outcomes. Furthermore, governments frequently provide funding for educational initiatives aimed at dispelling myths and common worries about vaccines, fostering community trust.
The Human Papillomavirus (HPV) vaccination campaign was initiated by the Government of Bangladesh in October 2023, with assistance from UNICEF, the Vaccine Alliance (Gavi), and the World Health Organisation (WHO). By preventing cervical cancer, a disease that kills thousands of women in Bangladesh each year, this program seeks to safeguard the health and future of millions of girls throughout the nation.
Increased Demand for DTaP Vaccines
The global vaccine market is expanding due to the rising demand for DTaP (Diphtheria, Tetanus, and Acellular Pertussis) vaccinations. The primary reason for this growth in demand is the need to address the rising incidence of diseases, including pertussis, tetanus, and diphtheria. The high birth rate and the growing acceptance of the pertussis vaccination are the main drivers of the DTaP vaccine market. The launch of combination vaccines with DTaP components also contribute to the growth of the market. To fulfill this growing need, governments and pharmaceutical companies are making investments in R&D, which is spurring innovation and growth in the global vaccine market.
In December 2023, India, Panacea Biotec, the biotechnology company, introduced EasyFourPol, a fully liquid pentavalent vaccination based on wP-IPV. Children are protected against five lethal diseases by the wP-IPV pentavalent vaccine: invasive infections caused by Haemophilus influenza type B, pertussis, polio, tetanus, and diphtheria. Furthermore, the company declared that Panacea Biotec Germany GmbH, its step-down, wholly owned subsidiary, had registered Valganciclovir 50 mg/mL powder for oral solution in Germany.
Growing Use of Conjugate Vaccines
The global vaccination market is expanding due to the increasing usage of conjugate vaccines. The use of conjugate vaccines has increased because of their success in lowering the incidence of diseases and promoting strong immunity, particularly in susceptible groups such as young children and newborns. Due to their proven ability to effectively target a variety of diseases, these vaccines are essential components of global immunization programs. Researchers have been able to build conjugate vaccines with increased features, broadening their usefulness across numerous diseases, primarily made possible through advancements in biotechnology and vaccine development.
The World Health Organization (WHO), in February 2024, granted prequalification (PQ) approval to SK Bioscience, a South Korean biotech and vaccine business dedicated to advancing human health from prevention to cure, for their typhoid conjugate vaccine (TCV), SKYTyphoid. The company has already gotten two influenza vaccinations and a varicella vaccine. This is its fourth WHO PQ.
North America Dominating the Market
The global vaccine market is dominated by North America. This dominance is primarily due to the region's robust immunization and health welfare programs, solid government policies, and sophisticated research skills. North America's position as a major player in the global vaccination industry is further cemented by the existence of respectable manufacturers and sufficient financing regulations. Furthermore, the region's emphasis on raising the coverage of immunizations through partnerships and government initiatives supports its continued growth and market leadership. Increased knowledge and understanding of vaccines in these nations motivate people to seek prompt medical care, which fuels demand for vaccine treatments and aids in the growth of the global vaccine market
Valneva SE, a specialty vaccine manufacturer, declared in November 2023 that IXCHIQ, a single-dose, live-attenuated vaccine developed by Valneva, has been approved by the FDA for the prevention of chikungunya virus (CHIKV)-related illness in people 18 years of age and older who are at an increased risk of exposure.
Future Market Scenario (2024 - 2031F)
By utilizing the skills and extensive knowledge of innovation leaders, major firms in the global vaccination market are cooperating to share next-generation vaccine platforms, helping them get past hurdles to competition.
To find new development opportunities, companies in the worldwide vaccine market are working on needle-free delivery and investigating emerging disease indications like CMV and glioblastoma, an aggressive form of cancer.
Nucleic acid-based vaccines have shown considerable promise in treating HIV and cancer. As a result, the global vaccine market is expected to rise at a promising rate.
Asthma, diabetes, and respiratory syncytial virus (RSV) infections are among the new disease categories that companies in the global vaccine market are investigating, and which have not yet been the subject of vaccine research.
Key Players Landscape and Outlook
To maximize benefits and increase their market share, major players in the global vaccine market are collaborating more and more. Through these partnerships, businesses may pool their knowledge, assets, and technological know-how to expedite vaccine research, expand manufacturing capabilities, and effectively tackle global health concerns. Companies can efficiently bring breakthrough vaccines to market by collaborating with other businesses to obtain complementary talents, share knowledge, and pool resources. This cooperative strategy ensures a more thorough response to public health demands, promotes research improvements, and improves the vaccination market, in addition to encouraging innovation.
A strategic alliance was announced on February 26, 2024, by Takeda and Biological E. Limited (BE), a well-known pharmaceutical and vaccine company in India, to expedite access to QDENGA (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003) multi-dose vials (MDVs). To boost national immunization programs, governments in endemic countries will eventually be able to purchase these doses by 2030 at the latest.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.